Lilly/BI gain Japan approval for first Lantus biosimilar
This article was originally published in Scrip
Executive Summary
Lilly and Boehringer Ingelheim have confirmed that they have received regulatory approval in Japan for their insulin glargine product as the first biosimilar version of Sanofi's Lantus, the first such local competition for the branded basal insulin analog.